Eligard

Advanced Prostate Cancer

Eligard is primarily used for the palliative treatment of advanced prostate cancer. Palliative treatment focuses on managing the disease and relieving symptoms to improve quality of life when a cure may not be possible. It is typically prescribed when the cancer has spread beyond the prostate gland to other parts of the body.

Hormone Therapy

This medication belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) agonists. It is a form of hormone therapy, also called androgen deprivation therapy. Because prostate cancer cells often depend on male hormones like testosterone to grow, reducing these hormones can help manage the disease. Eligard works by signaling the body to stop producing testosterone.

By lowering testosterone levels, Eligard may help:

• Slow or stop the growth of cancer cells.
• Shrink existing tumors.
• Delay the progression of the cancer.
• Relieve symptoms associated with advanced disease, such as bone pain or difficulty urinating.

While Eligard is effective at managing advanced prostate cancer and its symptoms, it is not considered a cure for the condition.

Hormone Suppression

Eligard belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) agonists. It works by affecting the pituitary gland, which is responsible for signaling the body to produce sex hormones.

When treatment first begins, the medication causes a temporary increase in the production of certain hormones. However, after continuous use, the pituitary gland stops sending signals to the testicles to produce testosterone. This results in testosterone levels falling to very low levels, similar to the levels seen after surgical removal of the testicles.

Impact on Prostate Cancer

Most prostate cancer cells require testosterone to grow and spread. By depriving these cells of the hormone they need, Eligard can:

• Slow the growth of the tumor.
• Shrink the size of the cancer.
• Help relieve symptoms associated with advanced prostate cancer.

Because Eligard is designed as a long-acting injection, it releases the medication slowly over several months to maintain these low hormone levels consistently.

Common Side Effects

• Hot flashes and night sweats
• Pain, swelling, or bruising at the injection site
• Fatigue or general weakness
• Nausea, vomiting, or constipation
• Muscle or joint pain
• Breast tenderness or enlargement
• Decreased sexual desire or erectile dysfunction
• Shrinking of the testicles

Serious Side Effects

Seek medical attention immediately if you experience any of the following:

• Signs of an allergic reaction, such as hives, rash, or swelling of the face, lips, or tongue
• Chest pain, rapid heartbeat, or shortness of breath
• Sudden numbness or weakness, particularly on one side of the body
• Difficulty urinating, painful urination, or blood in the urine
• Severe or worsening bone pain
• New or worsening depression or mood changes
• Signs of high blood sugar, such as extreme thirst or frequent urination
• Seizures

In the first few weeks of treatment, your testosterone levels may briefly increase before they drop. This can cause a temporary worsening of prostate cancer symptoms, such as increased bone pain or urinary issues.

Tumor Flare

During the first few weeks of treatment, Eligard causes a temporary increase in testosterone levels. This may lead to a temporary worsening of symptoms, known as a tumor flare. In some cases, this can cause bone pain, urinary tract obstruction, or pressure on the spinal cord. Patients with existing spinal lesions or urinary blockage are typically monitored closely during the start of therapy.

Heart and Blood Vessel Risks

There is an increased risk of developing heart disease, including heart attack, stroke, and sudden cardiac death, in men receiving this type of hormone therapy. Healthcare providers may monitor for signs of cardiovascular disease and manage risk factors like high blood pressure or high cholesterol.

Blood Sugar and Diabetes

Treatment with Eligard may increase the risk of developing diabetes or make it harder to control blood sugar in people who already have diabetes. Periodic monitoring of blood glucose or hemoglobin A1c levels is often recommended.

Heart Rhythm Changes

This medication may affect the electrical activity of the heart, a condition known as QT prolongation. This risk is higher in patients with a history of heart rhythm issues or those taking other medications that affect the heart's rhythm.

Bone Density Loss

Long-term use of hormone therapy can lead to a decrease in bone mineral density, which may increase the risk of bone fractures or osteoporosis.

Seizures

Seizures have been reported in patients receiving leuprolide. This risk may be higher in individuals with a history of seizures, epilepsy, or certain brain conditions, though it has occurred in patients without these factors.

Pituitary Apoplexy

In rare cases, a serious condition called pituitary apoplexy can occur, usually within two weeks of the first dose. Symptoms may include sudden headache, vomiting, vision changes, or mental status changes.

Pregnancy Warning

Eligard is not intended for use in women and can cause fetal harm if administered during pregnancy. It should not be used by anyone who is or may become pregnant.

Pregnancy

Eligard is contraindicated for use during pregnancy. Research and animal studies indicate that leuprolide, the active ingredient, can cause fetal harm or pregnancy loss when administered to a pregnant person. If pregnancy is suspected or confirmed during treatment, it is important to contact a healthcare provider immediately to discuss the potential risks to the fetus.

Contraception

Because Eligard can cause birth defects, healthcare providers usually recommend using effective non-hormonal birth control methods during treatment. Since this medication affects hormone levels, hormonal contraceptives may not be appropriate or effective.

Breastfeeding

It is currently unknown if leuprolide passes into human breast milk or what effects it may have on a nursing infant. Due to the potential for serious side effects in a breastfed child, individuals are encouraged to discuss the risks and benefits of breastfeeding with their doctor. A decision may be needed to either stop breastfeeding or stop the medication, depending on the clinical necessity of the treatment.

Available Forms

Eligard is available as a subcutaneous injection. It is supplied in a specialized kit designed for mixing and administration by a healthcare provider.

Kit Components

• Pre-filled Syringes: The kit contains syringes that hold the active drug and a liquid delivery system.
• Injectable Suspension: The contents of the syringes are mixed together immediately before administration to create a suspension for injection.

The medication is injected into the fatty tissue just beneath the skin, where it is slowly released into the body.

FDA Approval and Indications

Eligard is approved by the U.S. Food and Drug Administration (FDA) for the palliative treatment of advanced prostate cancer. In this context, palliative treatment is intended to manage symptoms and improve quality of life in cases where the cancer has progressed to an advanced stage.

Safety Communications

The FDA has issued safety communications regarding the class of medications known as gonadotropin-releasing hormone (GnRH) agonists, which includes Eligard. These communications were based on a review of several studies that suggested a potential increased risk of certain health conditions in men receiving these treatments, including:

• Diabetes
• Heart attack
• Sudden cardiac death
• Stroke

As a result of these findings, the FDA requires the inclusion of information about these risks in the prescribing information for all GnRH agonist products. Healthcare providers are encouraged to monitor patients for the development of diabetes and cardiovascular disease while they are using this medication.

Monitoring and Warnings

While Eligard does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program, the FDA-approved labeling includes warnings about the "tumor flare" phenomenon. This occurs when testosterone levels briefly rise at the start of treatment, which may cause a temporary worsening of symptoms. The labeling also emphasizes the need for periodic monitoring of serum testosterone and prostate-specific antigen (PSA) levels to ensure the medication is working effectively.

Insurance and Coverage

Eligard is a prescription medication administered by a healthcare professional, which means it is often covered under the medical benefit portion of insurance plans rather than the pharmacy benefit. For patients with Medicare, it is typically covered under Medicare Part B. The actual out-of-pocket cost will depend on the specific terms of the insurance policy, including deductibles and coinsurance requirements.

Administration Costs

Because Eligard requires specific preparation and must be injected by a medical professional, the total cost usually includes more than just the medication itself. Patients may encounter charges for:

• The office visit or clinic fee.
• The professional service fee for the injection procedure.
• The medication itself, which varies in price based on whether a one-month, three-month, four-month, or six-month dose is used.

Financial Support Options

Financial assistance may be available for eligible patients to help manage the costs of treatment. These options often include:

• Copay Savings Programs: Programs designed to reduce the out-of-pocket costs for patients with commercial insurance.
• Patient Assistance Programs: Programs that provide the medication at low or no cost to individuals who meet specific income requirements and lack adequate insurance coverage.

Patients are encouraged to speak with their healthcare provider's billing office or their insurance company to understand the expected costs before starting treatment.